Drug intelligence / Profile preview

HN3

Development stage: Preclinical
Modality: Antibody-Based Therapeutics

Overview

HN3 is a human heavy chain antibody designed for the therapy of hepatocellular carcinoma (HCC). It specifically targets Glypican-3 (GPC3), a protein highly expressed in HCC cells but not in normal adult tissues. HN3 has demonstrated high tumor accumulation and superior homogeneous distribution within tumors compared to conventional IgG antibodies like YP7. It is utilized as a drug carrier platform, particularly in photoimmunotherapy (PIT) when conjugated with agents like IR700, to deliver targeted therapeutic effects against HCC.

Targets

GPC3 (Glypican-3)

Beyond the preview

Go deeper on HN3.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HN3.

Explore the full profile